22 completed, 10 unknown, 4 available, 4 withdrawn. 21 Phase 2, 11 Phase 1, 7 Phase 3, 4 Early Phase 1, 4 Not applicable.
Follow 3-Iodobenzylguanidine: new trials by email Literature Review of 3-Iodobenzylguanidine trials Research Report on 3-Iodobenzylguanidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 2 | Not yet recruiting | New Approaches to Neuroblastoma Therapy Consortium | 118 | 2026-12-31 | 2026-08-21 |
| MIBG in Aging and Neurologic Disorders meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy - Lewy Body Disease, Dementia | Phase 4 | Enrolling by invitation | Mayo Clinic | 50 | 2023-05-08 | 2026-07-30 |
| A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Lutathera, Azedra - Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors | Phase 1 / Phase 2 | Withdrawn | David Bushnell | 2022-09-30 | 2024-04-29 | |
| Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors MIBG-I131 - Neuroendocrine Tumors | Phase 2 | Withdrawn | AC Camargo Cancer Center | 2021-02-04 | 2022-05-19 | |
| Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 2 | Active not recruiting | Children's Oncology Group | 41 | 2020-12-31 | 2025-10-27 |
| Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors 3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan - Neuroendocrine Tumors | Early Phase 1 | Completed | University of Michigan Rogel Cancer Center | 32 | 2020-10-19 | 2026-06-08 |
| A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects 131I-MIBG, 131-MIBG + Vorinostat - Neuroblastoma, Neuroectodermal Tumors | Phase 2 | Unknown | Jubilant DraxImage Inc. | 60 | 2019-10-21 | 2023-02-16 |
| Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction mIBG, Topotecan, Thiotepa - Very High Risk Neuroblastoma | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 34 | 2018-10-01 | 2025-09-02 |
| MIBG With Dinutuximab +/- Vorinostat 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 1 | Completed | New Approaches to Neuroblastoma Therapy Consortium | 45 | 2018-09-12 | 2025-04-16 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors 90Y-DOTA-3-Tyr-Octreotide, 131I-MIBG - Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Early Phase 1 | Active not recruiting | David Bushnell | 20 | 2017-05-07 | 2023-08-16 |
| International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking - Heart Failure | Phase 3 | Terminated | GE Healthcare | 395 | 2015-12-30 | 2019-05-22 |
| Response-based Treatment of High-risk Neuroblastoma Cisplatin, Doxorubicin, Etoposide - Newly Diagnosed High Risk Neuroblastoma | Phase 2 | Unknown | Samsung Medical Center | 54 | 2015-04-01 | 2016-05-24 |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma | Phase 1 | Withdrawn | University College, London | 2014-10-01 | 2015-12-21 | |
| 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat 131I-MIBG, Vincristine, Irinotecan - Neuroblastoma | Phase 2 | Completed | New Approaches to Neuroblastoma Therapy Consortium | 114 | 2014-07-01 | 2022-06-08 |
| MIBG Therapy for Patients With MIBG Avid Tumors MIBG - MIBG Avid Tumors | Phase 2 | Active not recruiting | Nationwide Children's Hospital | 65 | 2014-03-01 | 2025-05-13 |
| MIBG for Refractory Neuroblastoma and Pheochromocytoma 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF - Relapsed Neuroblastoma, Metastatic Pheochromocytoma | Not applicable | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2013-12-01 | 2025-12-18 |
| Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. AdreView (Iobenguane I 123 Injection) - Heart Failure (HF), Ventricular Dysfunction, Left | Phase 4 | Completed | GE Healthcare | 63 | 2013-08-01 | 2016-12-08 |
| 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT) - Neuroblastoma | Early Phase 1 | Terminated | Miguel Pampaloni | 10 | 2013-04-09 | 2021-05-14 |
| Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan - Ganglioneuroblastoma, Localized Resectable Neuroblastoma | Phase 1 | Completed | Children's Oncology Group | 99 | 2011-12-21 | 2026-01-23 |
Showing 20 of 55. Sign in to see all of them.
Neuroblastoma (34) · Pheochromocytoma (14) · Neuroendocrine Tumors (9) · Paraganglioma (8) · Neoplasms (6) · Recurrence (6) · Heart Failure (5) · Ganglioneuroblastoma (3) · Neoplasm Metastasis (2) · Cognitive Dysfunction (1) · Death, Sudden (1) · Dementia (1) · Disease (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Lewy Body Disease (1)
New Approaches to Neuroblastoma Therapy Consortium (8) · GE Healthcare (6) · University of California, San Francisco (4) · Children's Oncology Group (3) · David Bushnell (3) · Molecular Insight Pharmaceuticals, Inc. (3) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (2) · Jubilant DraxImage Inc. (2) · Samsung Medical Center (2) · AC Camargo Cancer Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Centre Oscar Lambret (1) · Children's Cancer and Leukaemia Group (1) · Children's Hospital Medical Center, Cincinnati (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
United States (43) · Canada (5) · France (4) · Germany (3) · Italy (2) · Netherlands (2) · Spain (2) · Switzerland (2) · Australia (1) · Austria (1) · Brazil (1) · Czechia (1) · Hungary (1) · Iran (1) · New Zealand (1)
Katherine K. Matthay, MD (4) · John M. Maris, MD (3) · Steven DuBois, MD (3) · David Bushnell, M.D. (2) · Frank Berthold, MD (2) · Gregory Yanik, MD (2) · Ami V Desai (1) · Anne Sophie Defachelles, MD (1) · Araz Marachelian, MD, MS (1) · Arnold Jacobson, M.D. (1) · Arnold Jacobson, MD (1) · Bennett Chin, MD (1) · Bradley Boeve, MD (1) · Brian D Weiss (1) · Brian Weiss, MD (1)
PMID 20188504, PMID 21193691, PMID 26666380, PMID 34028986, PMID 16421427, PMID 17369569, PMID 19171714, PMID 19636009, PMID 19660720, PMID 19805691, PMID 26742708, PMID 26773712, PMID 27465021, PMID 28511709, PMID 29099942, PMID 29307718, PMID 34270348, PMID 36472300, PMID 37574821, PMID 40549985
P01CA081403 (5), U10CA180886 (3), 2015 (2), P50CA174521 (2), P01CA217959 (1), U10CA098543 (1)